Shares of Intra-Cellular Therapies (ITCI) plummeted on Thursday as biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful. The drug failed to reduce patients' schizophrenia symptoms when compared to a placebo. SunTrust subsequently downgraded Intra-Cellular's stock to NEUTRAL from BUY and cut its price target to $15 from $60 based on the trial results. Leerink also slashed its price target to $29 from $95, but said the recent selloff was overdone.
More from Video
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money Video Wrap: Apple Rallies as Services Segment Takes Center Stage
There is a lot of Apple news to chew on Wednesday.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.